Cardiovascular Sciences, Inc. Pursues Agreement With Garden State Nutritionals
05 3월 2008 - 10:29PM
Marketwired
ORLANDO, FL , a client company of the award-winning University
of Florida Technology Incubator program and their recently
announced partner, Medical Technologies Home Enterprises, Inc., are
enthused to announce plans to pursue an agreement with Garden State
Nutritionals of West Caldwell, NJ. The Company will negotiate for
the manufacture, testing and packaging of a revised line of health
promotion supplements with a tie-in to some of the Company's other
interests.
John Martin, recently appointed to the Company's board of
directors, has previously worked with Garden State to produce a
very successful line of supplements that proved effective in the
programs of Weight Loss Forever International, Inc. of which Mr.
Martin was the founder and president. "It's exciting to develop a
new offering of effective nutritionals and supplements with a
company the quality and size of Garden State," exclaimed Mr. Martin
following a pivotal meeting last week in Orlando.
Garden State Nutritionals is a division of Vitaquest
International and the world's leading custom manufacturer of
nutritional products. GSN has been under continuous family
management for more than 30 years and boasts one of the world's
largest and most compliant manufacturing and testing facilities for
nutritional products. Long standing relationships with many of this
industry's most well established and highly regarded names
demonstrate evidence of the company's commitment to purity, quality
and service. Drawing upon a palette of more than 1200 quality
controlled ingredients, Garden State Nutritionals produces more
than 2000 new products annually.
"We are pleased to have chosen Garden State for the production
of our private label line of health promotion and protection
products," states the Company's CEO, Dr. Larry Hooper. He goes on
to explain that, "With their state-of-the-art technologies and
equipment, Garden State is able to bring the same level of quality,
regardless of the size of the batch. In addition, Garden State is
fully GMP compliant and has been awarded the National Nutritional
Foods Association coveted GMP 'A rating.'"
Arrangements have been made for representatives of
Cardiovascular Sciences, Inc. to travel to the corporate and
manufacturing facilities of Garden State Nutritionals in New Jersey
next week. The goal of the intended meetings will be to finalize
the formulations and line-ups of the Company's private label
offerings and negotiate for the manufacture and packaging of the
supplements.
About Cardiovascular Sciences
Cardiovascular Sciences, Inc. is an advanced medical device
company which is developing a novel technology platform to address
the problem of post-surgical and post-traumatic adhesions.
Adhesions and the complications of adhesions are a significant
problem worldwide for a wide range of specialists, including
general surgeons, cardiothoracic surgeons, orthopedic, plastic, and
ophthalmologic and otolaryngology specialists to name just some of
them. In addition, the veterinary field has a tremendous need for a
product that can prevent similar problems in a wide variety of
animals. The Company's unique materials and processes promise a
more cost-effective and decidedly more efficient and capable means
to deal with a problem that has been so devastating to so many.
Current sponsored research at the University of Central Florida
(UCF) and previously at other institutions indicate that The
Company is on the right path and progressing well.
In addition to the anti-adhesion technology, The Company owns
technology in a variety of other areas, including thrombo-resistant
coatings, enhanced intra-arterial balloon pumping catheters, cell
engineered vascular tissues, and a method for improved recovery of
the heart following cardioplegia. This yields a diversified
portfolio with projects in various stages of development.
www.cvsciences.org
Forward-looking statements in this release are made pursuant to
the Safe Harbor Provisions of the Private Securities Litigation
Reform Act of 1995. These forward-looking statements are subject to
certain risks, and uncertainties and actual results could differ
from those discussed. This material is information only and is not
an offer or solicitation to buy or sell the securities.
For more information contact: Cardiovascular Sciences Investor
Relations 800-858-7502 ir@cvsciences.org
Cardiovascular Sciences (CE) (USOTC:CVSC)
과거 데이터 주식 차트
부터 10월(10) 2024 으로 11월(11) 2024
Cardiovascular Sciences (CE) (USOTC:CVSC)
과거 데이터 주식 차트
부터 11월(11) 2023 으로 11월(11) 2024